Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $1,181,630.76 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 37,524 shares of Eton Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $31.49, for a total value of $1,181,630.76. Following the transaction, the insider owned 25,249 shares of the company’s stock, valued at $795,091.01. The trade was a 59.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock traded up $1.11 during trading on Wednesday, reaching $32.40. 442,334 shares of the company’s stock were exchanged, compared to its average volume of 358,595. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $887.50 million, a PE ratio of -462.79 and a beta of 0.82. Eton Pharmaceuticals, Inc. has a twelve month low of $13.09 and a twelve month high of $35.66. The firm’s fifty day moving average price is $26.33 and its 200-day moving average price is $19.94.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The business had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. As a group, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Eton Pharmaceuticals during the third quarter worth approximately $37,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $74,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $109,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

ETON has been the topic of a number of recent analyst reports. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. B. Riley Financial boosted their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $41.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.